1. Home
  2. NUVL vs KVYO Comparison

NUVL vs KVYO Comparison

Compare NUVL & KVYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$103.39

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Klaviyo Inc. Series A

KVYO

Klaviyo Inc. Series A

HOLD

Current Price

$22.15

Market Cap

7.7B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
KVYO
Founded
2017
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
7.7B
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
NUVL
KVYO
Price
$103.39
$22.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
23
Target Price
$135.00
$42.65
AVG Volume (30 Days)
581.9K
3.6M
Earning Date
02-26-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,153,988,000.00
Revenue This Year
N/A
$32.49
Revenue Next Year
N/A
$21.66
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.81
52 Week Low
$55.54
$22.15
52 Week High
$113.02
$49.55

Technical Indicators

Market Signals
Indicator
NUVL
KVYO
Relative Strength Index (RSI) 48.27 28.80
Support Level $100.19 $24.83
Resistance Level $107.51 $26.28
Average True Range (ATR) 4.89 1.45
MACD -0.41 -0.37
Stochastic Oscillator 36.14 2.87

Price Performance

Historical Comparison
NUVL
KVYO

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About KVYO Klaviyo Inc. Series A

Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.

Share on Social Networks: